News Vertex Pharmaceuticals Incorporated

Stocks

VRTX

US92532F1003

Pharmaceuticals

Market Closed - Nasdaq Other stock markets 16:00:00 2026-07-24 EDT			5-day change	1st Jan Change
477.36 ^USD	+0.90%		-1.78%	+5.29%

07-21	Morgan Stanley Downgrades Vertex Pharmaceuticals to Equalweight From Overweight, Adjusts PT to $15 From $19	MT
07-20	Goldman Sachs Adjusts Price Target on Vertex Pharmaceuticals to $652 From $641, Maintains Buy Rating	MT

All News

Mentions Relevance

07-21	Morgan Stanley Downgrades Vertex Pharmaceuticals to Equalweight From Overweight, Adjusts PT to $15 From $19	MT
07-20	Goldman Sachs Adjusts Price Target on Vertex Pharmaceuticals to $652 From $641, Maintains Buy Rating	MT
07-13	UBS Adjusts Vertex Pharmaceuticals Price Target to $585 From $545, Maintains Buy Rating	MT
07-09	RBC Capital Adjusts Vertex Pharmaceuticals Price Target to $577 From $570	MT
07-08	Jefferies Adjusts Vertex Pharmaceuticals Price Target to $610 From $580	MT
07-07	Vertex to Announce Second Quarter 2026 Financial Results on August 3rd	BU
07-07	IBT company Crinetics to be acquired by Vertex for USD10 billion	AN
07-07	Top Midday Gainers	MT
07-07	Vertex Pharmaceuticals' Acquisition of Crinetics Adds Rare-Disease Drugs, UBS Says	MT
07-07	Cantor Sees 'Clear Strategic Rationale' Behind Vertex's Buy of Crinetics -- Market Talk	DJ
07-07	Vertex Signs Letter of Intent (LOI) with the pan-Canadian Pharmaceutical Alliance for ALYFTREK for the Treatment of Cystic Fibrosis	AQ
07-07	RBC Capital Adjusts Vertex Pharmaceuticals Price Target to $570 From $543, Maintains Outperform Rating	MT
07-07	Vertex Pharmaceuticals to Buy Crinetics in $10 Billion Deal	MT
07-07	Baird Adjusts Price Target on Vertex Pharmaceuticals to $350 From $330	MT
07-07	Deals of the day-Mergers and acquisitions	RE
07-06	Vertex Pharmaceuticals to Acquire Crinetics Pharmaceuticals for $10 Billion	DJ
07-06	Vertex to buy Crinetics for $10 billion in rare-diseases push	RE
07-06	Vertex Pharmaceuticals to Buy Crinetics Pharmaceuticals	MT
07-06	Vertex to buy Crinetics in $10 billion deal	RE
07-06	Vertex to Acquire Crinetics Pharmaceuticals	BU
07-06	Vertex Pharmaceuticals Signs Letter Of Intent With Pan-Canadian Pharmaceutical Alliance For PrALYFTREK For Cystic Fibrosis Treatment	CI
07-06	Vertex Signs Letter of Intent for Cystic Fibrosis Therapy in Canada	MT
07-02	Vertex Pharmaceuticals Incorporated Receives Us Fda Approval for Expanded Use of Casgevy for Treatment of People Ages 2 Years and Older with Sickle Cell Disease or Transfusion-Dependent Beta Thalassemia	CI
07-02	Vertex Pharmaceuticals Says FDA Approves Expanded Use of Casgevy in Younger Children With Blood Disorders	MT
07-01	Vertex Announces US FDA Approval for Expanded Use of CASGEVY® for the Treatment of People Ages 2 Years and Older With Sickle Cell Disease or Transfusion-Dependent Beta Thalassemia	BU